Pulse oximetry is a widely used device for the clinical assessment of arterial oxygenation and pulse rate. The clinical applications, quality assessment, and limitations are discussed in this guideline.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Advancing Quality in Health Care Testing

Clinical and Laboratory Standards Institute (CLSI) is an international, interdisciplinary, nonprofit, standards developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the health care community. We are recognized worldwide for the application of our unique consensus process in the development of standards and guidelines for patient testing and related health care issues. Our process is based on the principle that consensus is an effective way to improve patient testing and health care services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

A document is published as a standard, guideline, or report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

CLSI’s voluntary consensus process establishes formal criteria for the following:

- Authorization of a project
- Development and open review of documents
- Revision of documents in response to users’ comments
- Acceptance of a document as a consensus standard or guideline

Invitation for Participation in the Consensus Process

Core to the development of all CLSI documents is the consensus process. Within the context and operation of CLSI, voluntary consensus is substantial agreement by materially affected, competent, and interested parties that may be obtained by following the consensus procedures defined in CLSI’s Administrative Procedures. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and are willing to accept the resulting agreement. CLSI documents are expected to undergo evaluation and modification in order to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

Comments on Candidate Drafts for Advancement

CLSI’s voluntary consensus process depends on experts who serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of a 45-day comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate. All comments along with the committee’s responses are retained on file at CLSI and are available upon request.

Comments on Published Documents

The comments of users of published CLSI documents are essential to the consensus process. Anyone may submit a comment. All comments are addressed according to the consensus process by a committee of experts. A summary of comments and committee responses is retained on file at CLSI and is available upon request. Readers are strongly encouraged to comment at any time on any document.

APPEALS PROCESS

CLSI consensus procedures include an appeals process that is described in detail in Section 8 of the Administrative Procedures.

VOLUNTEER PARTICIPATION

Health care professionals in all specialties are urged to volunteer for participation in CLSI projects.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
940 West Valley Road, Suite 1400
Wayne, PA 19087 USA
610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org
Abstract

Clinical and Laboratory Standards Institute document POCT11-A2—Pulse Oximetry; Approved Guideline—Second Edition provides recommendations for the use of pulse oximeters according to the path of workflow: decisions that need to be made before initiating monitoring; concerns during monitoring; interpretation of the data; and information management. Considerations that should accompany use of these instruments, including a thorough summary of the limitations of existing technology, have also been outlined.
Copyright ©2011 Clinical and Laboratory Standards Institute. Except as stated below, neither this publication nor any portion thereof may be adapted, copied, or otherwise reproduced, by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from Clinical and Laboratory Standards Institute (“CLSI”).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, contact the Executive Vice President, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087, USA.

Suggested Citation


Proposed Guideline
April 2001

Approved Guideline
January 2005

Approved Guideline—Second Edition
April 2011
Committee Membership

Consensus Committee on Point-of-Care Testing

James H. Nichols, PhD, DABCC, FACC
Chairholder
Baystate Medical Center
Springfield, Massachusetts, USA

Frank M. LaDuca, PhD
Vice-Chairholder
Polymer Technology Systems (PTS)
Indianapolis, Indiana, USA

Mary C. Coyle, MS, MT(ASCP)
Roche Diagnostics Corporation
Indianapolis, Indiana, USA

Peggy Mann, MS, MT(ASCP)
The University of Texas Medical Branch
Texas City, Texas, USA

Frank M. LaDuca, PhD
Vice-Chairholder
Polymer Technology Systems (PTS)
Indianapolis, Indiana, USA

Mary C. Coyle, MS, MT(ASCP)
Roche Diagnostics Corporation
Indianapolis, Indiana, USA

Peggy Mann, MS, MT(ASCP)
The University of Texas Medical Branch
Texas City, Texas, USA

Ann Chappie, MT(HHS)
FDA Center for Devices and Radiological Health
Rockville, Maryland, USA

Document Development Committee on Pulse Oximetry

Bruce Toben, RRT-NPS, CPFT
Chairholder
ITC Nexus Dx
Piscataway, New Jersey, USA

Ellis Jacobs, PhD, DABCC, FACB
Vice-Chairholder
NY City Health & Hospital Corporation
New York, New York, USA

Matthew W. Prior, PhD
Nonin Medical, Inc.
Plymouth, Minnesota, USA

Lois M. Schmidt, DA
Vice President, Standards Development

David E. Sterry, MT(ASCP)
Staff Liaison

Gregg L. Ruppel, MEd, RRT, RPFT, FAARC
St. Louis University Hospital
St. Louis, Missouri, USA

Ron Quicho, BS
Project Manager

Brian Walsh, MBA, RRT-NPS, FAARC, RPFT
Children’s Medical Center
Dallas, Texas, USA

Melissa A. Lewis, ELS
Editorial Manager

Sharon S. Ehrmeyer, PhD
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, USA

Staff

Clinical and Laboratory Standards Institute
Wayne, Pennsylvania, USA
Contents

Abstract ............................................................................................................................................ i

Committee Membership .................................................................................................................. iii

Foreword ........................................................................................................................................ vii

1 Scope .......................................................................................................................................... 1

2 Introduction .................................................................................................................................. 1

3 Standard Precautions ................................................................................................................... 3

4 Terminology .................................................................................................................................. 3
  4.1 A Note on Terminology ............................................................................................................ 3
  4.2 Definitions ............................................................................................................................... 3
  4.3 Abbreviations and Acronyms ................................................................................................. 4

5 Premonitoring ............................................................................................................................... 5
  5.1 Indications for Use .................................................................................................................. 5
  5.2 Environment of Use ............................................................................................................... 5
  5.3 Patient Assessment .................................................................................................................. 6
  5.4 Instrument ............................................................................................................................... 6
  5.5 Sensors and Sensor Site Selection and Preparation ................................................................. 7

6 Monitoring/Testing Session ......................................................................................................... 8
  6.1 Duration .................................................................................................................................. 8
  6.2 Instrument Settings ................................................................................................................. 9
  6.3 Quality of Signal .................................................................................................................... 10
  6.4 Troubleshooting ..................................................................................................................... 11

7 Interpretation ............................................................................................................................... 12
  7.1 Performance: Accuracy and Reliability ............................................................................... 13
  7.2 Sources of Error ..................................................................................................................... 14
  7.3 Interpretation of SpO2 Data .................................................................................................... 17

8 Information Management ............................................................................................................ 19
  8.1 Patient Records ...................................................................................................................... 19
  8.2 Memory Capacity .................................................................................................................... 19
  8.3 Trending .................................................................................................................................. 19
  8.4 Device Interfaces .................................................................................................................... 20
  8.5 Remote Use ............................................................................................................................ 20

9 Patent Ductus Arteriosus and Intercardiac Shunt Detection ....................................................... 20

10 Summary .................................................................................................................................... 20

References ......................................................................................................................................... 21

The Quality Management System Approach ............................................................................... 24

Related CLSI Reference Materials .............................................................................................. 25
Foreword

This guideline replaces the original document, HS03-A—*Pulse Oximetry; Approved Guideline*, to focus on the medical use of pulse oximetry devices. The guideline has been expanded to address standard precautions, pulse CO-oximetry, data trending, device interfaces, and patent ductus arteriosus and intercardiac shunt detection. In addition, this edition of the guideline includes illustrations of a revised depiction of the schematic representation of light transmission through tissue, transmittance and reflectance sensors, and a pulse oximetry plethysmograph tracing.

The ease of use, noninvasive nature, and low cost associated with pulse oximeters have resulted in their widespread use in diverse clinical settings by a wide variety of medical personnel, including physicians, nurses, respiratory care practitioners/therapists, paramedics, and other allied health personnel. There are certain principles that should guide the use of these instruments regardless of the setting. Concern has been expressed regarding the general lack of basic understanding by caregivers of the related physiology, technical operation, and limitations of pulse oximetry.\(^1\)\(^2\) Some conclude that inadequate knowledge of pulse oximetry could compromise patient safety and contribute to morbidity.\(^3\)\(^4\) This document presents guidance for the use of pulse oximeters and is organized on the basis of the path of workflow: decisions that need to be made before initiating monitoring; concerns during monitoring; interpretation of the data; and information management. Considerations that should accompany use of these instruments, including a summary of the limitations of existing technology, are highlighted.

Key Words

Hemoglobin, oximetry, oxygen, oxygen saturation, oxyhemoglobin, oxyhemoglobin saturation
Pulse Oximetry; Approved Guideline—Second Edition

1 Scope

This guideline describes important premonitoring, monitoring, and postmonitoring activities in the path of workflow for pulse oximetry, including clinical applications, quality assessment, and limitations.

This guideline is intended for use by all individuals involved in the path of workflow for pulse oximetry, including physicians, nurses, respiratory care practitioners/therapists, paramedics, clinical equipment services managers and technicians, and other allied health personnel.

The focus of this guideline is to provide guidance on the medical use of pulse oximetry devices. This guideline is not intended to be an examination of pulse oximetry literature or a detailed description of the technology. For this information, refer to the device documentation and review articles.5-8

2 Introduction

Multiwavelength laboratory oximeters use spectrophotometric absorption of a blood specimen to determine the percentage of hemoglobin saturated with oxygen and the percentage of dyshemoglobins (DysHbs). The variety of hemoglobins that can be detected by the multiwavelength laboratory oximeters varies by model. Pulse oximetry is a noninvasive method of estimating the arterial oxygen saturation and pulse rate (PR) from pulsatile absorption signals derived from a sensor placed on the skin. The principle is based on the fact that oxyhemoglobin (O₂Hb) and deoxyhemoglobin (HHb) have different absorption spectra (see Figure 1), at the commonly used wavelengths of 660 nm (red light) and 905 to 940 nm (infrared [IR] light).

![Absorption Spectra of O₂Hb and HHb](image)

**Figure 1. Absorption Spectra of O₂Hb and HHb**

The sensor consists of light sources (light-emitting diodes [LEDs]) at the red and IR wavelengths and a photodetector (photodiode). When light from the sensor passes into the tissue, a portion is absorbed and the photodetector measures the residual. A fixed amount of light is absorbed by tissue, including nonpulsatile blood, and a modulating amount is absorbed by the pulsating arterial inflow (see Figure 2).
Figure 2. Schematic Representation of Light Transmission Through Tissue. The amount of transmitted light is determined by light absorbed by the static tissue components, which are venous and static arterial blood and bone, muscles, etc., and the pulse added volume of the arterial blood. In the transmitted light, the pulsatile arterial signal ($AC$) is typically only about 0.5% to 5% from the total transmitted light (DC). Reprinted with permission from GE Healthcare.

The ratio ($R$) is quantitatively related to the oxygen saturation of arterial blood measured in a laboratory oximeter.

$$R = \frac{AC_{\text{red}}/DC_{\text{red}}}{AC_{\text{infrared}}/DC_{\text{infrared}}}$$

Because the mathematical relationship between oxygen saturation and $R$ is not fixed, pulse oximeter manufacturers calibrate their devices empirically using a laboratory oximeter and arterial blood from healthy human volunteers. Two wavelength pulse oximeters are unable to distinguish DysHb due to the inherent limitations of using only two wavelengths of light. But pulse CO-oximeters based on multiple wavelengths of light will report the presence of DysHb and provide measurements of these species. However, unlike multiwavelength laboratory oximeters, they cannot accurately measure these DysHbs at saturation lower than 100% or other DysHbs such as sulfhemoglobin (SulfHb).

Regardless of whether they have the ability to distinguish abnormal hemoglobin species, all currently manufactured noninvasive oximeters (pulse oximeters and pulse CO-oximeters) estimate only functional oxygen saturation.

$$Functional \ oxygen \ saturation = \frac{O_2 Hb}{(O_2 Hb + HHb)} \times 100$$
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in the most current edition of CLSI document HS01—A Quality Management System Model for Health Care. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:


POCT11-A2 addresses the QSEs indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Adapted from CLSI document HS01—A Quality Management System Model for Health Care.

Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, CLSI document GP26—Application of a Quality Management System Model for Laboratory Services defines a clinical laboratory path of workflow, which consists of three sequential processes: preexamination, examination, and postexamination. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

POCT11-A2 addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Adapted from CLSI document HS01—A Quality Management System Model for Health Care.
Related CLSI Reference Materials*

C46-A2  Blood Gas and pH Analysis and Related Measurements; Approved Guideline—Second Edition (2009). This document provides clear definitions of the quantities in current use, and provides a single source of information on appropriate specimen collection, preanalytical variables, calibration, and quality control for blood pH and gas analysis and related measurements.

H11-A4  Procedures for the Collection of Arterial Blood Specimens; Approved Standard—Fourth Edition (2004). This document provides principles for collecting, handling, and transporting arterial blood specimens to assist with reducing collection hazards and ensuring the integrity of the arterial specimen.

M29-A3  Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005). Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.

* CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.